Episode Details

This episode breaks down the ADHD medication landscape — from the chemical split between methylphenidate and amphetamine to why Vyvanse has been the top seller for over a decade. We explore the prodrug mechanism that gives Vyvanse its smooth profile, the tradeoffs patients face between families, and what competitors like Mydayis and Azstarys bring to the table. Then we look at the non-stimulant shift: Qelbree's rapid growth, centanafadine's novel triple-reuptake mechanism, and whether the definition of first-line treatment is changing under Vyvanse's feet. Episode #926940 — open it directly at myweirdprompts.com/926940